• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Black Diamond Therapeutics, Inc. - Common Stock (NQ:BDTX)

3.550 -0.050 (-1.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,286,143
Open 3.530
Bid (Size) 3.030 (300)
Ask (Size) 3.050 (100)
Prev. Close 3.600
Today's Range 3.475 - 3.900
52wk Range 1.930 - 4.940
Shares Outstanding 36,213,654
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study ↗
May 21, 2026
Black Diamond Therapeutics (NASDAQ:BDTX) reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the... 
Via MarketBeat
News headline image
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
May 21, 2026
From Black Diamond Therapeutics, Inc
Via GlobeNewswire

Performance

YTD
+42.6%
+42.6%
1 Month
+12.7%
+12.7%
3 Month
+54.3%
+54.3%
6 Month
-6.8%
-6.8%
1 Year
+74.9%
+74.9%

More News

Read More
News headline image
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
May 19, 2026
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 07, 2026
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
April 21, 2026
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 16, 2026
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
March 02, 2026
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
December 03, 2025
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
December 02, 2025
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
November 06, 2025
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 06, 2025
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗
October 10, 2025
Via Benzinga
News headline image
Black Diamond (BDTX) Q2 Loss Narrows 47% ↗
August 07, 2025
Via The Motley Fool
News headline image
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 07, 2025
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
May 29, 2025
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 12, 2025
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
March 31, 2025
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
These stocks have an unusual volume in today's session ↗
March 21, 2025
Via Chartmill
News headline image
Unusual volume stocks in Thursday's session ↗
March 20, 2025
Via Chartmill
News headline image
These stocks are the most active in today's session ↗
March 19, 2025
Via Chartmill
News headline image
What's going on in today's session ↗
March 19, 2025
Via Chartmill
News headline image
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High ↗
March 19, 2025
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
March 19, 2025
Via Benzinga
News headline image
Wednesday's session: gap up and gap down stocks ↗
March 19, 2025
Via Chartmill
News headline image
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million ↗
March 19, 2025
Via Benzinga

Frequently Asked Questions

Is Black Diamond Therapeutics, Inc. - Common Stock publicly traded?
Yes, Black Diamond Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Black Diamond Therapeutics, Inc. - Common Stock trade on?
Black Diamond Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Black Diamond Therapeutics, Inc. - Common Stock?
The ticker symbol for Black Diamond Therapeutics, Inc. - Common Stock is BDTX on the Nasdaq Stock Market
What is the current price of Black Diamond Therapeutics, Inc. - Common Stock?
The current price of Black Diamond Therapeutics, Inc. - Common Stock is 3.550
When was Black Diamond Therapeutics, Inc. - Common Stock last traded?
The last trade of Black Diamond Therapeutics, Inc. - Common Stock was at 05/21/26 04:00 PM ET
What is the market capitalization of Black Diamond Therapeutics, Inc. - Common Stock?
The market capitalization of Black Diamond Therapeutics, Inc. - Common Stock is 128.56M
How many shares of Black Diamond Therapeutics, Inc. - Common Stock are outstanding?
Black Diamond Therapeutics, Inc. - Common Stock has 129M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap